AUTO3
Phase 1/2Terminated 0 views this week 0 watching💤 Quiet
Interest: 14/100
14
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Conditions
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Trial Timeline
Sep 5, 2017 → Oct 19, 2023
NCT ID
NCT03287817About AUTO3
AUTO3 is a phase 1/2 stage product being developed by Autolus Therapeutics for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). The current trial status is terminated. This product is registered under clinical trial identifier NCT03287817. Target conditions include Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL).
What happened to similar drugs?
0 of 10 similar drugs in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) were approved
Approved (0) Terminated (1) Active (9)
🔄SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
🔄Axicabtagene Ciloleucel + Platinum-containing Salvage Chemotherapy + Cyclophosphamide + FludarabineGilead SciencesPhase 3
Hype Score Breakdown
Clinical
9
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03287817 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)